Liao Zhongxing, Milas Luka, Komaki Ritsuko, Stevens Craig, Cox James D
Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Am J Clin Oncol. 2003 Aug;26(4):S85-91. doi: 10.1097/01.COC.0000074307.55019.29.
Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and cancer, including cancers of the lung and esophagus. Inhibition of this enzyme with selective COX-2 inhibitors was found to enhance tumor response to radiation in preclinical studies, suggesting that these agents can improve the response of various cancers to radiotherapy. On the basis of these preclinical findings, clinical trials of the combination of celecoxib, a selective COX-2 inhibitor, with radiotherapy were initiated in patients with lung carcinoma and with chemoradiotherapy in patients with esophageal carcinoma. The rationale for using selective COX-2 inhibitors is discussed, and the current clinical protocols and the initial findings are described.
环氧化酶-2（COX-2）是一种在诸如炎症过程和癌症等病理状态下参与前列腺素生成的酶。该酶在癌前病变和癌症（包括肺癌和食管癌）中常过度表达。在临床前研究中发现，用选择性COX-2抑制剂抑制这种酶可增强肿瘤对放疗的反应，这表明这些药物可改善各种癌症对放疗的反应。基于这些临床前研究结果，在肺癌患者中启动了选择性COX-2抑制剂塞来昔布与放疗联合应用的临床试验，并在食管癌患者中启动了其与放化疗联合应用的临床试验。文中讨论了使用选择性COX-2抑制剂的基本原理，并描述了当前的临床方案和初步研究结果。
